公开(公告)号：US20230181769A1

公开(公告)日：2023-06-15

申请号：US17641787

申请日：2020-09-10

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Nicholas C. Allen ,  Paula J. Bates ,  Martin G. O'Toole

IPC: A61K49/18 ,  A61K47/69 ,  A61K47/60 ,  A61P35/00

CPC classification number: A61K49/186 ,  A61K47/6929 ,  A61K47/60 ,  A61P35/00

Abstract: A composition comprises an anti-nucleolin agent and PEG conjugated to nanoparticles. Preferably the nanoparticles have an average diameter of 1 to 50 nm. Preferably, the nanopanicles comprise at least one inorganic material selected from the group consisting of metals, elements and oxides.

公开(公告)号：US11344633B2

公开(公告)日：2022-05-31

申请号：US15240780

申请日：2016-08-18

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Paula J. Bates ,  Mohammad Tariq Malik ,  Kyung A. Kang

IPC: A61K47/69 ,  A61P35/00 ,  A61K49/04 ,  A61K47/62 ,  A61K47/61

Abstract: A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.

公开(公告)号：US09737493B2

公开(公告)日：2017-08-22

申请号：US14426399

申请日：2013-09-06

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Francesca R. Salipur ,  Paula J. Bates ,  Elsa Merit Reyes-Reyes ,  Bo Xu ,  Gerald B. Hammond

IPC: A61K31/45 ,  A61K31/198 ,  A61K31/045 ,  A61K45/06 ,  A61K31/22 ,  A61K38/06

CPC classification number: A61K31/045 ,  A61K31/198 ,  A61K31/22 ,  A61K38/063 ,  A61K45/06 ,  A61K2300/00

Abstract: Some aspects of the invention include attenuating DNMT1 inhibitor activity in an animal comprising administering an antioxidant. Other aspects of the invention include methods comprising administering a composition comprising a DNMT1 inhibitor and an antioxidant. In some instances in the methods, the animal is undergoing a treatment for cancer. Additional aspects of the invention include compositions comprising a DNMT1 inhibitor and an antioxidant.

公开(公告)号：US20170095562A1

公开(公告)日：2017-04-06

申请号：US15240780

申请日：2016-08-18

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Paula J. Bates ,  Mohammad Tariq Malik ,  Kyung A. Kang

IPC: A61K49/04

CPC classification number: A61K49/04 ,  A61K47/61 ,  A61K47/62 ,  A61K47/6923 ,  A61K47/6929 ,  A61P35/00 ,  Y10T428/2982

Abstract: A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.

公开(公告)号：US20220265867A1

公开(公告)日：2022-08-25

申请号：US17741686

申请日：2022-05-11

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Paula J. Bates ,  Mohammad Tariq Malik ,  Kyung A. Kang

IPC: A61K49/04 ,  A61K47/62 ,  A61K47/61 ,  A61K47/69 ,  A61P35/00

Abstract: A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.

公开(公告)号：US20150025129A1

公开(公告)日：2015-01-22

申请号：US14358731

申请日：2012-11-16

Applicant: University of Louisville Research Foundation, Inc ,  Laboratorios de Investigacion y Desarrollo: Facult de Ciencias y Filosofia

Inventor： Gerald B. Hammond ,  Zhuang Jin ,  Paula J. Bates ,  Elsa Merit Reyes-Reyes ,  Abraham Vaisberg

IPC: A61K31/366 ,  A61K36/81

CPC classification number: A61K31/366 ,  A61K36/81

Abstract: Certain embodiments of the invention include compositions comprising a compound of Formula (I), and salts, isomers, and derivatives thereof. Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I), and salts, isomers, and derivatives thereof. Other embodiments of this invention include methods for treating disease (e.g., cancer) and methods for administering a compound of Formula (I), and salts, isomers, and derivatives thereof.

Abstract translation: 本发明的某些实施方案包括包含式（I）化合物及其盐，异构体及其衍生物的组合物。 本发明一些实施方案的药物组合物包含式（I）化合物及其盐，异构体及其衍生物。 本发明的其它实施方案包括治疗疾病（例如癌症）的方法和给予式（I）化合物及其盐，异构体及其衍生物的方法。

公开(公告)号：US11208379B2

公开(公告)日：2021-12-28

申请号：US16672481

申请日：2019-11-03

Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

Inventor： Craig A. Grapperhaus ,  Robert M. Buchanan ,  Nicholas S. Vishnosky ,  Jason O. E. Young ,  Paula J. Bates ,  Sarah A. Andres ,  Caleb Aaron Calvary

IPC: C07C335/40 ,  A61P35/00 ,  C07D265/30

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

公开(公告)号：US10857237B2

公开(公告)日：2020-12-08

申请号：US15571763

申请日：2016-05-05

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Mohammad Tariq Malik ,  Martin G. O'Toole ,  Paula J. Bates

IPC: A61K49/00 ,  A61K47/69 ,  A61K41/00 ,  A61K49/04 ,  A61K31/28 ,  A61K45/06 ,  A61K31/7105 ,  A61K49/18 ,  A61K9/00 ,  A61K47/54 ,  A61P35/00 ,  C07K16/18 ,  C07K16/30 ,  C12N15/115

Abstract: A composition comprises an anti-nucleolin agent conjugated to nanoparticles, and optionally containing gadolinium. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier. The composition enhances the effectiveness of radiation therapy, enhancing contrast in X-ray imaging techniques, and when gadolinium is present, provide cancer selective MRI contrast agents.

公开(公告)号：US09492428B2

公开(公告)日：2016-11-15

申请号：US14358731

申请日：2012-11-16

Applicant: University of Louisville Research Foundation, Inc. ,  Cayetano Heredia University

Inventor： Gerald B. Hammond ,  Zhuang Jin ,  Paula J. Bates ,  Elsa Merit Reyes-Reyes ,  Abraham Vaisberg

IPC: A61K31/366 ,  A61K36/81

CPC classification number: A61K31/366 ,  A61K36/81

Abstract: Certain embodiments of the invention include compositions comprising a compound of Formula (I), and salts, isomers, and derivatives thereof. Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I), and salts, isomers, and derivatives thereof. Other embodiments of this invention include methods for treating disease (e.g., cancer) and methods for administering a compound of Formula (I), and salts, isomers, and derivatives thereof.

Abstract translation: 本发明的某些实施方案包括包含式（I）化合物及其盐，异构体及其衍生物的组合物。 本发明一些实施方案的药物组合物包含式（I）化合物及其盐，异构体及其衍生物。 本发明的其它实施方案包括治疗疾病（例如癌症）的方法和给予式（I）化合物及其盐，异构体及其衍生物的方法。

公开(公告)号：US20150238439A1

公开(公告)日：2015-08-27

申请号：US14426399

申请日：2013-09-06

Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

Inventor： Francesca R. Salipur ,  Paula J. Bates ,  Elsa Merit Reyes-Reyes ,  Bo Xu ,  Gerald B. Hammond

IPC: A61K31/045 ,  A61K38/06 ,  A61K31/22 ,  A61K31/198

CPC classification number: A61K31/045 ,  A61K31/198 ,  A61K31/22 ,  A61K38/063 ,  A61K45/06 ,  A61K2300/00

Abstract: Some aspects of the invention include attenuating DNMT1 inhibitor activity in an animal comprising administering an antioxidant. Other aspects of the invention include methods comprising administering a composition comprising a DNMT1 inhibitor and an antioxidant. In some instances in the methods, the animal is undergoing a treatment for cancer. Additional aspects of the invention include compositions comprising a DNMT1 inhibitor and an antioxidant.

Abstract translation: 本发明的一些方面包括减轻动物中的DNMT1抑制剂活性，包括施用抗氧化剂。 本发明的其它方面包括施用包含DNMT1抑制剂和抗氧化剂的组合物的方法。 在这些方法的某些情况下，动物正在接受癌症治疗。 本发明的另外的方面包括含有DNMT1抑制剂和抗氧化剂的组合物。